A Randomized Phase III Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03906071

Study #:
849-001STUDY00144726

Start Date:
Feb 04, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03906071

View Complete Trial Details & Eligibility at ClinicalTrials.gov